siRNA Therapeutics for HAE
Clinical Milestone: Argo Biopharma Reports 100% Attack Reduction in HAE Phase II Trial
In a significant update for the Hereditary Angioedema (HAE) community, Argo Biopharmaceutical has announced positive Phase II interim results for BW-20805, its investigational siRNA therapeutic. The data, presented as a late-breaking abstract at the 2026 AAAAI Annual Meeting, highlights the drug’s potential as a “best-in-class” long-acting prophylactic. I’m seeing a clear shift in the HAE…
